Search results for "Adverse effect"

showing 10 items of 1065 documents

A Narrative Review about Nutritional Management and Prevention of Oral Mucositis in Haematology and Oncology Cancer Patients Undergoing Antineoplasti…

2021

Cancer is a prevalent disease worldwide, and treatments such as radiotherapy and chemotherapy sometimes lead to adverse events. Oral mucositis is one of the most disabling adverse events, and clinical guidelines do not take into account nutritional interventions. The primary endpoint was to gather the evidence about the efficacy of nutritional interventions in the prevention and/or treatment of antineoplastic-induced oral mucositis in oncological patients. A bibliographic review was carried out in the PubMed data base by combining MeSH terms with Boolean operators. Articles were selected based on inclusion and exclusion criteria; 50 final articles were found. Although further evidence is ne…

AdultMalemedicine.medical_specialtyDiet therapyGlutaminemedicine.medical_treatmentAntineoplastic AgentsReviewDiseaseNeoplasmsmedicineMucositisClinical endpointHumanscancerTX341-641ChildAdverse effectIntensive care medicineStomatitisNutrition and DieteticsNutrition. Foods and food supplybusiness.industryCancerHoneyVitaminsmedicine.diseaseRadiation therapyTreatment Outcomediet therapyDietary SupplementsInclusion and exclusion criteriaFemalebusinessoral mucositisFood ScienceNutrients
researchProduct

Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry

2020

Abstract Background and Aims Although commonly used in inflammatory bowel disease [IBD], thiopurines frequently cause intolerance, and switching to a second thiopurine has only been reported in some small series. Ours aims in this study were to evaluate the safety of switching to a second thiopurine in a large cohort, and to assess the impact of age on tolerance. Methods Adult IBD patients from the ENEIDA registry, who were switched to a second thiopurine due to adverse events [excluding malignancies and infections], were identified. At the beginning of thiopurine treatment, patients were divided by age into two groups: 18–50 and over 60 years of age. The rate and concordance of adverse eve…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsConcordanceInflammatory bowel diseaseelderly03 medical and health sciences0302 clinical medicineinflammatory bowel diseaseInternal medicineAzathioprinemedicineHumans030212 general & internal medicinePractice Patterns Physicians'Adverse effectThiopurine elderly inflammatory bowel diseaseAgedThiopurine methyltransferasebiologyThiopurinebusiness.industryDrug SubstitutionMercaptopurineGastroenterologyAge FactorsGeneral MedicineOdds ratioDrug Tolerancemedicine.diseaseInflammatory Bowel DiseasesConfidence intervaldigestive system diseasesClinical PracticeSpainbiology.proteinAcute pancreatitis030211 gastroenterology & hepatologyFemaleRisk AdjustmentDrug MonitoringbusinessImmunosuppressive Agents
researchProduct

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

2018

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859 ) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506 ). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-def…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsExacerbationInjections Subcutaneous[SDV]Life Sciences [q-bio]ImmunologyEosinophilic asthmaAntibodies Monoclonal HumanizedPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodSurveys and QuestionnairesInternal medicineEosinophiliamedicineHumansImmunology and AllergyIn patientAnti-Asthmatic Agents030212 general & internal medicineAdverse effectRespiratory Tract InfectionsComputingMilieux_MISCELLANEOUSAsthmabusiness.industryMiddle Agedmedicine.diseaseAsthma3. Good healthEosinophils[SDV] Life Sciences [q-bio]Treatment Outcome030228 respiratory systemAsthma Control QuestionnaireBronchitisFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial

2019

Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. Objective Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. Design Open-label, phase II proof-of-concept study. Setting Multicenter. Patients Fifteen with GD. Intervention Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. Main outcome measures Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. Results The iscalima…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismGraves' diseasemedicine.medical_treatmentClinical BiochemistryContext (language use)Thyroid Function TestsHyperthyroidismProof of Concept StudyBiochemistryGastroenterologyThyrotropin receptorYoung AdultEndocrinologyThyroid peroxidaseInternal medicinemedicineHumansTissue DistributionCD40 AntigensAdverse effectAgedTriiodothyroninebiologybusiness.industryBiochemistry (medical)AutoantibodyAntibodies MonoclonalMiddle AgedPrognosismedicine.diseaseEndocrinologybiology.proteinFemaleThyroglobulinbusinessFollow-Up StudiesThe Journal of Clinical Endocrinology & Metabolism
researchProduct

The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: The SURGE 2 practice-based study

2013

SURGE 2, a large-scale, practice-based study in 10 countries, evaluated the effects of telmisartan alone or with hydrochlorothiazide (HCTZ) on morning (06:00 – 11:59) home blood pressure (HBP) control. Hypertensive patients (clinic blood pressure [BP] 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12.5 mg for 8 weeks. Treatment could be adjusted if clinic BP remained 140/90 mmHg. Clinic BP was measured in the morning prior to medication, and seated HBP monitoring was performed, three times per day, 2 days per week. A total of 25,882 patients were included (71% were previously using antihypertensives). There was a statistically signifi cant (all p 0.00…

AdultMalemedicine.medical_specialtyEveningAdolescentDiastoleBlood PressureBenzoatesYoung AdultHydrochlorothiazideInternal medicineInternal MedicinemedicineHumansProspective StudiesTelmisartanProspective cohort studyAdverse effectAntihypertensive AgentsMorningAgedAged 80 and overbusiness.industryHome blood pressure monitoring hydrochlorothiazide morning blood pressure control telmisartanGeneral MedicineMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedDrug CombinationsEndocrinologyBlood pressureHydrochlorothiazideAnesthesiaHypertensionBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

2009

Abstract Introduction Hypersensitivity reaction to abacavir (a powerful inverse transcriptase inhibitor) is a serious adverse effect that limits its use in antiretroviral treatment and requires a high level of clinical surveillance. Certain haplotypes of the primary histocompatibility complex proteins (HLA-B*5701) are very significant predictors of the risk of hypersensitivity to this drug. The purpose of this study is to identify the cases where a probable hypersensitivity reaction to abacavir presented the HLA-B*5701 allele. Method A retrospective study was conducted in all HIV-1 positive adult patients infected treated with abacavir between January 2000 and December 2007, in Department 6…

AdultMalemedicine.medical_specialtyFeverGenotypeAnti-HIV AgentsGastrointestinal DiseasesGenes MHC Class IHIV InfectionsPharmacotherapyAbacavirInternal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseAdverse effectAgedRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedRashDideoxynucleosidesHypersensitivity reactionHLA-B AntigensImmunologyHIV-1Reverse Transcriptase InhibitorsFemaleDrug Eruptionsmedicine.symptombusinessPharmacogeneticsmedicine.drugFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
researchProduct

Failure to renew prescriptions for gastroprotective agents to patients on continuous nonsteroidal anti-inflammatory drugs increases rate of upper gas…

2013

Patients with risk factors for gastrointestinal (GI) disorders who continuously use nonsteroidal anti-inflammatory drugs (NSAIDs) also should take gastroprotective agents (GPAs), such as proton pump inhibitors (PPIs). However, it is not clear how many physicians continue to prescribe GPAs to these patients, and whether stopping the GPA prescription increases GI complications.We performed a retrospective, observational, longitudinal study using a validated electronic database of representative general practitioners in France. We analyzed data for 1856 patients at risk for GI events (65 y, past history of GI ulcer, or receiving antiplatelet agents) who received prescriptions for an NSAID and …

AdultMalemedicine.medical_specialtyGastrointestinal DiseasesLogistic regressionGastrointestinal AgentsInternal medicinemedicineHumansLongitudinal StudiesMedical prescriptionAdverse effectAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryHazard ratioAnti-Inflammatory Agents Non-SteroidalGastroenterologyRetrospective cohort studyOdds ratioMiddle AgedConfidence intervalSurgeryFemaleFranceComplicationbusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C

2010

Purpose Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs. Methods Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting. Results Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (<5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, re…

AdultMalemedicine.medical_specialtyGenotypeEpidemiologyadverse eventHepacivirusAntiviral AgentsSettore MED/01 - Statistica MedicaMedication Adherencechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinHumansMedicinePharmacology (medical)Dual therapyAdverse effectDose ModificationSettore MED/12 - GastroenterologiaDose-Response Relationship Drugbusiness.industryIncidenceRibavirinAge FactorsAntiviral therapyInterferon-alphainterferonpredictionHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryDiscontinuationchemistryDrug Therapy CombinationFemalehepatitis CbusinessPharmacoepidemiology and Drug Safety
researchProduct

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients…

2008

Background/Aims The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown. Methods Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-α2b and ribavirin for 48 weeks. Results In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adher…

AdultMalemedicine.medical_specialtyHBsAgCombination therapyHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis B ChronicPegylated interferonInternal medicineRibavirinmedicineHumansProspective StudiesAdverse effectAgedHepatitis B virusHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis C ChronicMiddle AgedRecombinant Proteinsdigestive system diseaseschemistryDNA ViralImmunologyRNA ViralFemaleViral diseasebusinessmedicine.drugJournal of Hepatology
researchProduct

Nurses' perceptions of the benefits and adverse effects of hand disinfection: alcohol-based hand rubs vs. hygienic handwashing: a multicentre questio…

2008

Summary Background  Nurses have a high risk of developing hand eczema due to hand disinfection procedures. Objectives  To investigate the perception of nurses regarding the adverse effects of hand washing (HW) and alcoholic disinfection (ADI), and to obtain data on the prevalence of hand dermatitis and sensitization to alcohols and alcohol-based hand rubs (ABHRs). Methods  A self-administered questionnaire survey, carried out as a pilot study (PS), followed by a modified multicentre study (MC) in five hospitals. Patch tests to ethanol (80%), 1-propanol (60%), 2-propanol (70%) and ABHRs were performed in a subsample. Results  The majority (PS 60·1%; MC 69·5%) of nurses considered ADI to be m…

AdultMalemedicine.medical_specialtyHand washingAttitude of Health Personnelmedia_common.quotation_subjectOccupational diseasePilot ProjectsDermatologyHand DermatosesNursing Staff HospitalDermatitis ContactAge DistributionHygieneInternal medicineGermanymedicineHumansSex DistributionAdverse effectmedia_commonEthanolbusiness.industryHygieneMiddle AgedPatch Testsmedicine.diseaseSurgeryDisinfectionTolerabilityDermatitis OccupationalHand eczemaIrritant contact dermatitisAnti-Infective Agents LocalFemalebusinessContact dermatitisHand DisinfectionThe British journal of dermatology
researchProduct